Status:

COMPLETED

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Lead Sponsor:

CSL Behring

Conditions:

Primary Immune Deficiency Disorder

Eligibility:

All Genders

Up to 75 years

Phase:

PHASE3

Brief Summary

The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06\_002CR (N...

Eligibility Criteria

Inclusion

  • Subjects who have participated in study ZLB06\_002CR and who have tolerated IgPro20 well.
  • Written informed consent by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years at the time of obtaining informed consent), as far as possible.

Exclusion

  • Ongoing serious bacterial infections (SBIs) (pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of the first infusion.
  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (known total urine protein concentration \>0.2 g/L or urine protein ++ by dipstick).
  • Pregnancy or nursing mother.
  • Participation in a study with an investigational medicinal product (IMP) within 3 months prior to enrollment except for ZLB06\_002CR.
  • Subjects who are planning to donate blood during the study.
  • Re-entry of subjects previously participating in the current follow-up study.
  • Known or suspected antibodies to the IMP, or to excipients of the IMP.

Key Trial Info

Start Date :

April 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2012

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT01458171

Start Date

April 1 2011

End Date

April 1 2012

Last Update

April 9 2013

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Study site

Nagoya, Aichi Pref., Japan, 466-8560

2

Study site

Chiba, Chiba Pref., Japan, 260-8677

3

Study site

Fukuoka, Fukuoka, Japan, 812-8582

4

Study site

Gifu, Gifu Pref., Japan, 502-8558

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) | DecenTrialz